Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Payables (2019 - 2025)

Volitionrx (VNRX) has disclosed Payables for 9 consecutive years, with $4.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 86.86% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Sep 2025, up 86.86%, and an annual FY2024 reading of $2.8 million, down 13.86% over the prior year.
  • Payables was $4.6 million for Q3 2025 at Volitionrx, up from $2.5 million in the prior quarter.
  • Across five years, Payables topped out at $4.6 million in Q3 2025 and bottomed at $1.1 million in Q2 2021.
  • Average Payables over 5 years is $2.7 million, with a median of $2.9 million recorded in 2023.
  • The sharpest move saw Payables surged 140.24% in 2022, then fell 24.8% in 2025.
  • Year by year, Payables stood at $1.5 million in 2021, then surged by 97.28% to $3.0 million in 2022, then increased by 5.53% to $3.2 million in 2023, then dropped by 13.86% to $2.8 million in 2024, then surged by 67.87% to $4.6 million in 2025.
  • Business Quant data shows Payables for VNRX at $4.6 million in Q3 2025, $2.5 million in Q2 2025, and $3.0 million in Q1 2025.